Wall Street Analysts Believe Nuvation Bio (NUVB) Could Rally 25.14%: Here's is How to TradeZacks Investment Research • 12/19/25
Innovent Announces Inclusion of Seven Innovative Drugs including TYVYT New Indication and SYCUME in China's National Reimbursement Drug ListPRNewsWire • 12/07/25
Nuvation Bio Inc. (NUVB) Presents at Citi Annual Global Healthcare Conference 2025 TranscriptSeeking Alpha • 12/03/25
Nuvation Bio Announces Publication of Positive Phase 2 Study Results for Safusidenib for the Treatment of Grade 2 IDH1-Mutant Glioma in Neuro-OncologyBusiness Wire • 12/03/25
Nuvation Bio Inc. (NUVB) Presents at Jefferies London Healthcare Conference 2025 TranscriptSeeking Alpha • 11/22/25
Nuvation Bio Reports Third Quarter 2025 Financial Results and Provides Business UpdateBusiness Wire • 11/03/25
Nuvation Bio Chief Scientist Sells 100,000 Shares Under Trading Plan — Here's What to Know About the StockThe Motley Fool • 11/03/25
Nuvation Bio Enrolls First Patient in Global, Randomized Study of Safusidenib for Maintenance Treatment of High-Grade IDH1-Mutant GliomaBusiness Wire • 10/23/25
Nuvation Bio to Report Third Quarter 2025 Financial Results and Provide Business Update on November 3, 2025Business Wire • 10/20/25
Nuvation Bio Enrolls First Patient in TRUST-IV Phase 3 Study of IBTROZI™ (taletrectinib) for the Adjuvant Treatment of ROS1-Positive Early-Stage Non-Small Cell Lung CancerBusiness Wire • 09/30/25
Nuvation Bio Receives Approval from Japan's Ministry of Health, Labour and Welfare for IBTROZITM for Patients with Advanced ROS1-positive Non-Small Cell Lung CancerBusiness Wire • 09/19/25
Nuvation Bio Announces New Data from Pivotal Clinical Studies of IBTROZI™ (taletrectinib) in Advanced ROS1-Positive Non-Small Cell Lung Cancer at 2025 World Conference on Lung CancerBusiness Wire • 09/07/25
Nuvation Bio Inc. (NUVB) Just Flashed Golden Cross Signal: Do You Buy?Zacks Investment Research • 08/27/25
Nuvation Bio Reports Second Quarter 2025 Financial Results and Provides Business UpdateBusiness Wire • 08/07/25